Aminocaproic Acid

This page contains recent news articles, when available, and an overview of Aminocaproic Acid but does not offer medical advice. You should contact your physician with regard to any health issues or concerns.

Anti-bleeding drug raises death risk — study  -  May 15, 2008
For every 100 patients getting tranexamic acid or aminocaproic acid, four died, according to the study, published electronically on Wednesday by the New TheChronicleHerald.ca,

A Comparison of Aprotinin and Lysine Analogues in High-Risk ...  -  May 28, 2008
We sought to determine whether aprotinin was superior to either tranexamic acid or aminocaproic acid in decreasing massive postoperative bleeding and other New England Journal of Medicine (subscription),

BART Closes the Book on Aprotinin  -  May 20, 2008
Compare the effect of aprotinin with tranexamic acid vs aminocaproic acid for preventing massive bleeding after high-risk cardiac surgery. Medscape (subscription)

Drug aprotinin boosts risk of death: study  -  May 14, 2008
..."Overall, our study supports the use of tranexamic acid or aminocaproic acid over aprotinin during high-risk heart surgery," stressed Dr. Paul Hebert, AFP

Breastfeeding May Prevent Arthritis, Antifibrinolytic Agents ...  -  May 14, 2008
...about 6% of patients who received aprotinin died within 30 days of surgery compared to 4% of patients who received tranexamic acid or aminocaproic acid. Insider Medicine,

It's Game Over for Trasylol, but Bayer Refuses to Fold  -  May 25, 2008
...patients using aprotinin (Trasylol) were more likely to die than patients administered alternatives--specifically, tranexamic acid or aminocaproic acid. Lawyers and Settlements

Aprotinin (Trasylol) Use in CABG Again Shows Extra Mortality Risk  -  Feb 20, 2008
Patients treated with aprotinin had an almost a two-fold greater mortality compared with patients given aminocaproic acid during heart surgery, MedPage Today,

Suspended heart surgery drug linked to higher death risk, averse ...  -  Feb 20, 2008
...in high risk cardiac patients designed to compare the more expensive aprotinin to two cheaper drugs in the class, aminocaproic acid or tranexamic acid. The Canadian Press

Aprotinin during Coronary-Artery Bypass Grafting and Risk of Death  -  Feb 20, 2008
Postoperative revascularization and dialysis were more frequent among recipients of aprotinin than among recipients of aminocaproic acid. New England Journal of Medicine (subscription),

Bayer hurt by damaging Trasylol data, sued over Kogenate  -  Feb 21, 2008
33517 patients received Trasylol and 44682 were given aminocaproic acid. Overall, 1512 aprotinin patients (4.5%) and 1101 aminocaproic acid patients (2.5%) Pharma Times (subscription),

The Effect of Aprotinin on Outcome after Coronary-Artery Bypass ...  -  Feb 20, 2008
As compared with the use of aminocaproic acid or no antifibrinolytic agent, aprotinin use was also associated with a larger risk-adjusted increase in the New England Journal of Medicine (subscription),

More Evidence of Danger From Heart Surgery Drug  -  Feb 20, 2008
The mortality rate for those taking Trasylol was also 27 percent higher than those given aminocaproic acid, a different medication used to limit bleeding. Washington Post,

Aprotinin under fire: Two new observational studies point to ...  -  Feb 20, 2008
They report that 4.5% of more than 33 500 aprotinin recipients died, vs 2.5% of 44 682 aminocaproic-acid recipients. "The most important finding in our TheHeart.Org,

Cardiac Surgery Drug Increases Death Rate, Study Confirms  -  Feb 23, 2008
Patients who received either aminocaproic acid or no therapy did not have high rates of death or poor kidney function seen in the aprotinin group. Science Daily (press release)

Bayer Responds to Trasylol Studies  -  Feb 22, 2008
Bayer believes that the database selected was unsuitable for comparing the safety of Trasylol and aminocaproic acid (commonly used to reduce bleeding- InjuryBoard.com,

More Evidence Condemns Trasylol and FDA  -  Feb 21, 2008
And the death rate was higher by 27 percent among those given Trasylol over a competing and standard medication used to limit bleeding, aminocaproic acid. InjuryBoard.com,

Guidelines Issued for Diagnosis and Management of von Willebrand's ...  -  Mar 5, 2008
The antifibrinolytic drugs aminocaproic acid and tranexamic acid can also be used to treat mild mucocutaneous bleeding in VWD. Concentrates of VWF can be Medscape (subscription)

Drug used in cardiac surgery increases death rate  -  Feb 20, 2008
Of the 10275 patients studied in the new study, 1343 (13.2 percent) received Aprotinin, 6776 (66.8 percent) received Aminocaproic acid - another drug used KalingaTimes,

Aprotinin Safe in On-Pump but Not Off-Pump CABG  -  Feb 13, 2008
He adds that in the meantime, many centers are now using alternative products such as epsilon-aminocaproic acid or tranexamic acid, "but no one has really Medscape (subscription)

Bayer Drug Alleged to Have Led to 22000 Deaths  -  Feb 19, 2008
Trasylol was 20.8 percent, compared to 15.8 percent for those given another drug, aminocaproic acid, and 14.7 percent for those given tranexamic acid. Best Syndication,

Bayer's Trasylol Boosts Death, Kidney Risks After Heart Surgery  -  Feb 20, 2008
...analyzed the data and accounted for differences between the patients getting Trasylol and those on the alternate, generic drug aminocaproic acid. Bloomberg

LeftBlog: An ppen letter to Congressman Dr. Charles Boustany Jr.  -  Feb 19, 2008
Both of these medications Aminocaproic acid and Tranexamic acid respectively, act without the renal damage or the $1000 price tag of Trasylol. The Daily Advertiser,

FDA Fails - The Story of Joseph Randone  -  Feb 17, 2008
In contrast, the less expensive generic medications aminocaproic acid and tranexamic acid are safe alternatives." In the case of Trasylol, Bayer hired a InjuryBoard.com,

Bayer pulls Leukine from US, positive Nexavar news in Japan  -  Jan 24, 2008
...a higher risk of death amongst those given Trasylol compared with two older antifibrinolytic agents, epsilon-aminocaproic acid and tranexamic acid. Pharma Times (subscription),

UK Regulator Investigating Trasylol, Pulls Licenses  -  Jan 8, 2008
The BART study was doing just that—comparing the effectiveness of aprotinin against alternatives such as lysosine analogues, aminocaproic acid and Lawyers and Settlements

Health Canada Issues an Update on Availability of Trasylol (aprotinin)  -  Nov 26, 2007
The study was designed to compare Trasylol to epsilon-aminocaproic acid and tranexamic acid in decreasing the occurrence of massive bleeding associated with DG News

Surgery for Acquired Cardiovascular Disease  -  Dec 11, 2007
In our early experience, some patients did receive epsilon aminocaproic acid; however, in this series, the majority of patients, nearly 90%, had received The Journal of Thoracic and Cardiovascular Surgery

RIFLE criteria for acute kidney injury in aortic arch surgery  -  Dec 11, 2007
Aprotinin was administered to 239 (88.8%), and the remainder received epsilon aminocaproic acid; these groups differed significantly only in that more The Journal of Thoracic and Cardiovascular Surgery

EMEA advisors call for suspension for Bayer's Trasylol  -  Nov 23, 2007
...findings indicated a higher risk of death compared to two antifibrinolytic drugs used in the study, epsilon-aminocaproic acid and tranexamic acid. Pharma Times (subscription),

Basics of Blood Management  -  Dec 4, 2007
These drugs, including desmopressin, epsilon-aminocaproic acid, aprotinin, fibrin sealants, and collagen are frequently used during surgical procedures. Journal of American Medical Association (subscription),

Trasylol Kills: Somebody Tell Bayer and the FDA  -  Nov 13, 2007
The exhaustive study involved 78199 patients, and compared recipients of aprotinin (Trasylol) versus aminocaproic acid among patients undergoing Coronary Lawyers and Settlements

Aprotinin (Trasylol) Marketing Halted Over Suspected Mortality Risk  -  Nov 5, 2007
The researchers planned to enroll 3000 patients for randomization to aprotinin, epsilon-aminocaproic acid, or tranexamic acid. The 30-day mortality in the MedPage Today,

Bayer Trasylol study halted  -  Oct 30, 2007
...aminocaproic acid and tranexamic acid in approximately 3000 high-risk cardiac surgical patients undergoing either re-operation for coronary heart bypass Pharmaceutical Business Review

Excess Deaths Shut Down Aprotinin (Trasylol) Arm of Heart Surgery ...  -  Oct 26, 2007
The researchers planned to enroll 3000 Canadian patients for randomization to aprotinin, epsilon-aminocaproic acid, or tranexamic acid. MedPage Today,

FDA Issues an Early Communication about an Ongoing Safety Review ...  -  Oct 25, 2007
The preliminary findings suggest that, compared to the antifibrinolytic drugs, epsilon-aminocaproic acid and tranexamic acid, aprotinin increases the risk PharmaLive.com (press release),

Trasylol (aprotinin) Trial Stopped Due to Adverse Effects  -  Oct 27, 2007
...in preventing excessive post-cardiac surgery bleeding, as compared to other antifibrinolytics, such as, epsilon-aminocaproic acid and tranexamic acid. MedHeadlines,

Bayer halts sales of anti-bleeding drug after Canadian trial ...  -  Nov 5, 2007
Antifibrinolytics in a Randomized Trial - was designed to test the efficacy of aprotinin and two related drugs, tranexamic acid and aminocaproic acid. The Canadian Press

Local docs ponder use of pulled anti-bleeding drug  -  Nov 7, 2007
Two other drugs, aminocaproic acid and tranexamic acid, are also used to help stop excessive bleeding. Robinson said he doesn't use either drug "on a Newsday,

Heart surgery drug withdrawn worldwide  -  Nov 6, 2007
Apart from the lack of substantial health risks, other drugs such as aminocaproic acid and tranexamic acid are also far less expensive. Hindustan Times,

Bayer halts drug sales after study links it to risks  -  Nov 6, 2007
...of deaths among patients who received Trasylol than those who received the drugs it was being tested against, aminocaproic acid and tranexamic acid. Toronto Star,

Trasylol Pulled From Worldwide Market  -  Nov 5, 2007
The five-year death rate for patients given Trasylol was 20.8 percent, compared to 15.8 percent for those given another drug, aminocaproic acid, U.S. News & World Report,

Canadian trial prompts Bayer to halt marketing drug  -  Nov 5, 2007
It is a multi-centre randomized controlled trial to compare the efficacy and safety of aprotinin, aminocaproic acid and tranexamic acid. CTV.ca,

Canadian Trial Of Heart Surgery Drug Trasylol Halted  -  Oct 26, 2007
...appeared to be at a higher risk of death compared to patients treated with the other two antifibrinolytic drugs, aminocaproic acid and tranexamic acid. Medical News Today,

Bayer Halts Trials on Trasylol Used in Bypass Surgery  -  Oct 27, 2007
The aim of the trial, known by its acronym BART, is to compare the effectiveness and safety of aprotinin, aminocaproic acid and tranexamic acid — three MedIndia,

Bayer's Trasylol back in the dock as Canadian study is stopped  -  Oct 26, 2007
Preliminary findings suggest that Trasylol increases the risk of death compared to two antifibrinolytic drugs used in the study, epsilon-aminocaproic acid Pharma Times (subscription),

Sale of heart Surgery Drug Suspended by Bayer  -  Nov 6, 2007
The BART trial which was the first to test aprotinin against other drugs tested it against tranexamic acid and aminocaproic acid, which are all used to stem Earthtimes,

Bayer Pulls Heart Surgery Drug Trasylol  -  Nov 6, 2007
...also linked with an increased risk of death due to all causes compared to patients on two other antifibrinolytics, aminocaproic acid or tranexamic acid. Medical News Today,

Bayer suspends sales of Trasylol on safety concerns  -  Nov 6, 2007
...findings indicated a higher risk of death compared to two antifibrinolytic drugs used in the study, epsilon-aminocaproic acid and tranexamic acid. Pharma Times (subscription),

Bayer pulls its anti-clotting drug 'Trasylol' from market  -  Nov 6, 2007
...epsilon-aminocaproic acid (10g loading dose + 2g/hr on CPB), or tranexamic acid (30mg/kg loading dose + 2mg/kg pump prime + 16mg/kg/hr on CPB). The Money Times,

Bayer yanks aprotinin off the market pending analysis of BART  -  Nov 5, 2007
...patients receiving aprotinin died within the first 30 days of the trial, as compared with patients taking epsilon-aminocaproic acid or tranexamic acid. TheHeart.Org,

Trasylol: AG Bayer Halts Global Sales of Troubled Drug  -  Nov 5, 2007
They were to be randomly assigned one of three drugs that were being used for comparison purposes: aprotinin, aminocaproic acid, and tranexamic acid. Lawyers and Settlements,

Bayer Temporarily Suspends Global Trasylol(R) Marketing  -  Nov 5, 2007
...for 30- day mortality) for patients in the aprotinin treatment arm compared to patients who received either aminocaproic acid or tranexamic acid. PR Newswire (press release),

Trial Examines Blood Conservation Using Antifibrinolytics  -  Nov 2, 2007
The three drugs examined, aminocaproic acid, aprotinin and tranexamic acid, were all approved by Health Canada and were not considered investigational. eMaxHealth.com,

FDA Indicates Trasylol May Increase Death Risk  -  Oct 29, 2007
Those drugs are epsilon-aminocaproic acid and tranexamic acid. It was determined that a continued enrollment of patients into the study would not change the Associated Content,

Trial of Heart Surgery Drug Trasylol Halted; FDA issues new guidelines  -  Oct 27, 2007
The patients on Trasylol (aprotinin) appeared to be at a higher risk of death as compared to patients treated with the other two drugs, aminocaproic acid TopNews,

Bayer Trasylol trial halted due to high risk of death  -  Oct 26, 2007
The study was meant to determine if aprotinin is superior to other antifibrinolytic drugs such as epsilon-aminocaproic acid or tranexamic acid. Food Consumer,

Aprotinin-related mortality risk puts brakes on randomized surgery ...  -  Oct 25, 2007
BART had been designed to determine whether aprotinin would be better than either epsilon-aminocaproic acid or tranexamic acid in preventing "massive TheHeart.Org,

Human error blamed by lawyer for Trasylol blunders at Bayer  -  Aug 20, 2007
...study commissioned by the company to analyse the effects of aprotinin, aminocaproic acid and tranexamic acid in patients undergoing CABG surgery. Pharma Times (subscription),

Long-term Mortality Associated With Aprotinin Following Coronary ...  -  Jun 12, 2007
Journal of American Medical Association (subscription),Since European and Asian centers could not contribute any information with respect to aminocaproic acid, only patients from North and South America,

Evaluating the safety implications of aprotinin use: The ...  -  Jun 4, 2007
The Journal of Thoracic and Cardiovascular SurgeryCost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeat cardiac operations: a randomized, blinded clinical

Trasylol Likely Cause of Death  -  May 22, 2007
Lawyers and Settlements,And here is the kicker: In the majority of cases, a patient can be given other drugs (generic medications aminocaproic acid and tranexamic acid ) that have

Trasylol: The Side Effects Could Kill You  -  Apr 29, 2007
Lawyers and Settlements,Alternatives that are known to be reliable and effective, such as aminocaproic acid and tranexamic acid, are also far less expensive than Trasylol aprotinin

:

Disclaimer:

Contact a physician with regard to health concerns. Email requests for further health information will be discarded.

The materials contained on this Web site are for informational purposes only and do not constitute health or medical advice. Use of information on this site does not create or constitute any kind of agreement or contract between you and the owners or users of this site, the owners of the servers upon which it is housed, or anyone else who is in any way connected with this site.

Many links on health.mongabay.com lead to other sites. health.mongabay.com does not sponsor, endorse or otherwise approve of the materials appearing in such sites. Nor is health.mongabay.com responsible for dead or misdirected links.